EP 1224201 A4 20050302 - 32 HUMAN SECRETED PROTEINS
Title (en)
32 HUMAN SECRETED PROTEINS
Title (de)
32 VOM MENSCHEN ABGESONDERTE PROTEINE
Title (fr)
32 PROTEINES HUMAINES SECRETEES
Publication
Application
Priority
- US 0029363 W 20001025
- US 16223999 P 19991029
- US 21513900 P 20000630
Abstract (en)
[origin: WO0132675A1] The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
IPC 1-7
C07H 21/04; C07H 21/02; C07K 5/00; C07K 14/00; C12Q 1/68; C12N 1/21; C12N 15/63; C12N 15/85; C12N 15/86
IPC 8 full level
C12N 15/09 (2006.01); A61K 31/7088 (2006.01); A61K 35/76 (2006.01); A61K 38/00 (2006.01); A61K 38/22 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01); A61P 5/00 (2006.01); A61P 5/10 (2006.01); A61P 7/00 (2006.01); A61P 7/02 (2006.01); A61P 7/04 (2006.01); A61P 7/06 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 11/06 (2006.01); A61P 13/12 (2006.01); A61P 15/08 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01); A61P 21/04 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 31/18 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); A61P 37/08 (2006.01); A61P 43/00 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12P 21/02 (2006.01); C12Q 1/68 (2006.01)
CPC (source: EP)
A61P 1/16 (2017.12); A61P 3/10 (2017.12); A61P 5/00 (2017.12); A61P 5/10 (2017.12); A61P 7/00 (2017.12); A61P 7/02 (2017.12); A61P 7/04 (2017.12); A61P 7/06 (2017.12); A61P 9/00 (2017.12); A61P 9/10 (2017.12); A61P 11/06 (2017.12); A61P 13/12 (2017.12); A61P 15/08 (2017.12); A61P 17/00 (2017.12); A61P 19/02 (2017.12); A61P 21/04 (2017.12); A61P 25/00 (2017.12); A61P 25/16 (2017.12); A61P 25/28 (2017.12); A61P 27/02 (2017.12); A61P 29/00 (2017.12); A61P 31/18 (2017.12); A61P 35/00 (2017.12); A61P 37/04 (2017.12); A61P 37/08 (2017.12); A61P 43/00 (2017.12); C07K 14/47 (2013.01)
Citation (search report)
- [PX] WO 0053750 A1 20000914 - GENENTECH INC [US], et al
- [PX] WO 0012708 A2 20000309 - GENENTECH INC [US], et al
- [E] WO 0078961 A1 20001228 - GENENTECH INC [US], et al
- [Y] WO 9947540 A1 19990923 - HUMAN GENOME SCIENCES INC [US], et al
- [Y] WO 9801552 A2 19980115 - GENETICS INST [US]
- [E] EP 1067182 A2 20010110 - HELIX RES INST [JP]
- [E] WO 0118016 A1 20010315 - MILLENNIUM PHARM INC [US]
- [XY] DATABASE EMBL EMBL; 30 August 1999 (1999-08-30), KOEHRER ET AL, XP002298528, retrieved from EBI accession no. HSM800846 Database accession no. AL110276
- [Y] LANGER-SAFER P R ET AL: "STRATEGIES FOR THE APPLICATION OF FUNCTIONAL GENOMICS TECHNOLOGY TO BIOPHARMACEUTICAL DRUG DISCOVERY", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 41, no. 3/4, July 1997 (1997-07-01), pages 173 - 179, XP001117948, ISSN: 0272-4391
- [Y] CELIS J E ET AL: "SECRETED PROTEINS FROM NORMAL AND SV40 TRANSFORMED HUMAN MRC-5 FIBROBLASTS: TOWARD ESTABLISHING A DATABASE OF HUMAN SECRETED PROTEINS", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 1, no. 10, October 1987 (1987-10-01), pages 707 - 717, XP001118789, ISSN: 0887-6924
- See references of WO 0132675A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0132675 A1 20010510; AU 1342501 A 20010514; CA 2386641 A1 20010510; EP 1224201 A1 20020724; EP 1224201 A4 20050302; JP 2003528586 A 20030930
DOCDB simple family (application)
US 0029363 W 20001025; AU 1342501 A 20001025; CA 2386641 A 20001025; EP 00975362 A 20001025; JP 2001535376 A 20001025